The Chronic Disease Conundrum - Takeaways - MDSpire
Feature

The Chronic Disease Conundrum

Russ Lebovitz and Arnon Chait on why we need smarter biomarkers to guide clinically actionable diagnostics in an aging population

  • By

  • Jessica Allerton

  • May 14, 2026

  • 7 min

Share

  • 1

    Current diagnostics show limitations amid rising chronic diseases.

  • 2

    Emphasis on biology-driven diagnostics to identify diseases earlier.

  • 3

    Need for precise biomarkers in neurodegenerative diseases and cancer.

  • 4

    Diagnostics should guide clinical decisions more effectively.

  • 5

    Structured pathways can minimize unnecessary procedures.

  • 6

    Laboratories must adapt to improve diagnostic capabilities and support patient-centered care.

Original Source(s)

The Chronic Disease Conundrum

  • by Jessica Allerton

  • May 14, 2026

Related Content

Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was associated with higher rates of excellent 90-day outcomes after inadequate tenecteplase response in selected stroke patients, though adjusted analyses were not significant.

Tenecteplase Prior to EVT Did Not Improve Stroke Outcomes

Phase 3 trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.

New Label Expansion in Generalized Myasthenia Gravis

Phase 3 ADAPT SERON data supported efgartigimod use across antibody subtypes often underrepresented in trials.